Compare Dollar General Corp. (DG) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Enveric Biosciences Inc — how do they compare? Dollar General Corp. trades at $124.44 (market cap $27.42B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.80M). The key difference: Dollar General Corp. is far larger — about 4032.4× Enveric Biosciences Inc's market cap, and Dollar General Corp. pays a 1.9% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Enveric Biosciences Inc for 14 Days on average.
| DG | ENVB | |
|---|---|---|
Market Cap | $27.42B | $6.80M |
Volume | 2,291,517 | 64,867 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $10.80 |
52-Week Low | $95.94 | $1.27 |
Typical Hold Time | 59 Days | 14 Days |
Enterprise Value | $41.60B | -$1.49M |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $122.16, down 0.89% on the day, with a neutral technical signal. The stock shows strong fundamentals with a P/E of 16.14 and P/S of 0.63, indicating potential undervaluation. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $2.48 surpassing the $2.01 expectation. Positive news includes tariff refunds boosting margins and expansion of same-day delivery via Instacart, supporting growth initiatives.
The outlook is cautiously optimistic, with a consensus price target of $137.27 offering ~12% upside. Key opportunities include margin improvement from operational initiatives, while risks involve competitive pressures and potential consumer spending softness. Analyst sentiment is predominantly buy-rated (55.77%), though recent insider selling and mixed technical indicators warrant monitoring.
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
